Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA9 | Q16790 | 5/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | IDE | P14735 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14417100 | 0.76 | TDP1 (0.55) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL6033324 | 0.76 | TDP1 (0.55) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL18780618 | 0.76 | TDP1 (0.55) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL179912 | 0.76 | TDP1 (0.55) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL12569327 | 0.76 | TDP1 (0.55) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL4455260 | 0.76 | TDP1 (0.55) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL19543512 | 0.76 | TDP1 (0.71) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL12352865 | 0.76 | TDP1 (0.71) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL20369791 | 0.76 | TDP1 (0.71) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL8428342 | 0.76 | TDP1 (0.49) | TDP1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4296270-A2 | A COMPOSITION COMPRISING STEM CELL CULTURES | The Scripps Research Institute (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-3936508-B1 | A COMPOSITION COMPRISING STEM CELL CULTURES | SCRIPPS RESEARCH INST (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-3936508-A1 | A COMPOSITION COMPRISING STEM CELL CULTURES | The Scripps Research Institute (US) | 2022-01-12 | — | — | EP | disclosed |
| US-20210403862-A1 | METHODS OF ENHANCING CELL SURVIVAL OF STEM CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2021-12-30 | — | — | US | disclosed |
| EP-3623374-B1 | STEM CELL CULTURES | SCRIPPS RESEARCH INST (US) | 2021-09-08 | — | — | EP | disclosed |
| US-10975352-B2 | Methods of enhancing cell survival of stem cells | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-13 | — | — | US | disclosed |
| EP-3623374-A1 | STEM CELL CULTURES | The Scripps Research Institute (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-3441394-B1 | STEM CELL CULTURES | SCRIPPS RESEARCH INST (US) | 2020-01-29 | — | — | EP | disclosed |
| US-20190352600-A1 | METHODS OF ENHANCING CELL SURVIVAL OF STEM CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2019-11-21 | — | — | US | disclosed |
| US-10351822-B2 | Methods of enhancing cell survival of stem cells | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-07-16 | — | — | US | disclosed |
| EP-2789618-B1 | Stem cell cultures | SCRIPPS RESEARCH INST (US) | 2016-07-27 | — | — | EP | disclosed |
| US-9340525-B2 | Stem cell cultures | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-05-17 | — | — | US | disclosed |
| EP-2789618-A1 | Stem cell cultures | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20140273214-A1 | STEM CELL CULTURES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-09-18 | — | — | US | disclosed |
| EP-2370445-B1 | STEM CELL CULTURES | SCRIPPS RESEARCH INST (US) | 2014-07-23 | — | — | EP | disclosed |
| US-20110294761-A1 | STEM CELL CULTURES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-01 | — | — | US | disclosed |
| US-8044201-B2 | Stem cell cultures | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2370445-A1 | STEM CELL CULTURES | The Scripps Research Institute (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20110224233-A1 | STEM CELL CULTURES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-09-15 | — | — | US | disclosed |
| WO-2010065721-A1 | STEM CELL CULTURES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352600-A1 | METHODS OF ENHANCING CELL SURVIVAL OF STEM CELLS | MCL1, BCL2, BCLAF1 | TDP1 1968/4885CA12 2156/4885CA1 1125/4885 |
| US-20140273214-A1 | STEM CELL CULTURES | NES, CD44, MCL1 | TDP1 3090/4885CA12 862/4885CA1 1171/4885 |
| US-10975352-B2 | Methods of enhancing cell survival of stem cells | MCL1, BCL2, BCLAF1 | TDP1 1968/4885CA12 2156/4885CA1 1125/4885 |
| US-10351822-B2 | Methods of enhancing cell survival of stem cells | MCL1, BCL2, BCLAF1 | TDP1 1968/4885CA12 2156/4885CA1 1125/4885 |
| US-20110294761-A1 | STEM CELL CULTURES | NES, CD44, MCL1 | TDP1 3090/4885CA12 862/4885CA1 1171/4885 |
| US-20210403862-A1 | METHODS OF ENHANCING CELL SURVIVAL OF STEM CELLS | MCL1, BCL2, BCLAF1 | TDP1 1968/4885CA12 2156/4885CA1 1125/4885 |
| US-20110224233-A1 | STEM CELL CULTURES | NES, CD44, MCL1 | TDP1 3090/4885CA12 862/4885CA1 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.